Hyaluronate Sodium
CAS 9067-32-7
Hyaluronate Sodium (CAS 9067-32-7) is a pharmaceutical compound with 0 bioactivity targets and 122 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Hyaluronate Sodium is linked to DTXSID30238233 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| HYALURONATE SODIUM | 42892 | SU | MTHSPL |
| Hyaluronate Sodium | 42892 | SU | MTHSPL |
| hyaluronate sodium | 42892 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Hyaluronate Sodium used for in pharmaceutical contexts?
Hyaluronate Sodium (CAS 9067-32-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Hyaluronate Sodium?
Hyaluronate Sodium has 122 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain lower, Acute kidney injury, Alanine aminotransferase increased, Alopecia, Anaemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Hyaluronate Sodium also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Hyaluronate with EU status "permitted".
What clinical phase is Hyaluronate Sodium in?
No phase 1-4 clinical development badge is rendered for Hyaluronate Sodium because the matched compound identifier rows do not contain a max-phase value.